Pamiparib

Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class.

In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy.

It is currently under investigation for the treatment of other forms of cancer.